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A liposome formulation for paclitaxel was developed in this study. The liposomes, composed of naturally unsaturated and
hydrogenated phosphatidylcholines, with signiﬁcant phase transition temperature diﬀerence, were prepared and characterized.
The liposomes exhibited a high content of paclitaxel, which was incorporated within the segregated microdomains coexisting on
phospholipid bilayer of liposomes. As much as 15% paclitaxel to phospholipid molar ratio were attained without precipitates
observed during preparation. In addition, the liposomes remained stable in liquid form at 4◦C for at least 6 months. The special
composition of liposomal membrane which could reduce paclitaxel aggregation could account for such a capacity and stability.
The cytotoxicity of prepared paclitaxel liposomes on the colon cancer C-26 cell culture was comparable to Taxol. Acute toxicity
test revealed that LD50 for intravenous bolus injection in mice exceeded by 40mg/kg. In antitumor eﬃcacy study, the prepared
liposomal paclitaxel demonstrated the increase in the eﬃcacy against human cancer in animal model. Taken together, the novel
formulated liposomes can incorporate high content of paclitaxel, remaining stable for long-term storage. These animal data also
demonstrate that the liposomal paclitaxel is promising for further clinical use.
1.Introduction
Paclitaxel, an eﬀective anticancer agent, has been applied
as the ﬁrst-line drug against breast and ovarian cancers.
However, more extensive clinical use is limited owing to
the drug’s low water solubility and the highly inﬂammatory
response to the current excipient, cremophore EL [1]. Thus,
much eﬀort has been made in eliminating the side eﬀects
during administration. A variety of formulations have been
developed to replace cremophore EL [2–12]. Among those
formulations, liposome is regarded as one of the most
promising drug carrier. It has many advantages over other
formulations, such as being the most biocompatible and
best able to reduce drug toxicity without changing drug
eﬃcacy against tumor cells. However, limited drug loading
and insuﬃcient shelf stability remain prohibitive obstacles to
practical application [1, 2, 12].
Conventional paclitaxel liposomes were prepared at a
conﬁned paclitaxel/lipid molar ratio of approximately 3%,
regardless of whether the liposomes were made of a mixture
of phosphatidyl glycerol (PG) [13, 14] or DOTAP (1,2-
dioleoyl-3-trimethylammonium propane) [15]a n dp h o s -
phatidyl choline (PC), or unsaturated [16, 17] or partially
unsaturated PC [18]. At a drug-to-lipid molar ratio of 4%,
the paclitaxel-liposomes are stable for only 2 days. Dur-
ing preparation of paclitaxel liposomes, needle-like crystal
precipitates appear at a drug/lipid molar ratio up to 8%
[19]. Incorporation of the hydrophilic polymer conjugated
phospholipid (methoxy polyethylene glycol-phosphatidyl
ethanolamine), known to be able to stabilize liposomes and
extend its circulation time in the bloodstream, that was
attempted[20].ButthePEGylatedliposomeswithamaximal
paclitaxel/lipidmolarratioof3%quicklybecomeunstablein
one week of storage at 4◦C. On the other hand, the liposomal
formulations of paclitaxel consisting of a special negatively
charged phospholipid, cardiolipid, and phosphatidyl choline
have been described [21]. Increasing the paclitaxel/lipid
molar ratio to 9% causes the liposomes to be stable for only
one month when stored in liquid form at 4◦C[ 21]. For the
3% drug-to-lipid ratio of liposomal paclitaxel, it needs many2 Journal of Drug Delivery
lipids to formulate, thus increases the cost of lipids and the
volume for injection in clinical, and would be signiﬁcantly
more expensive than the commercial product (Taxol).
Korlach et al. reported the presence of a phase
separation in giant unilamellar vesicles composed of
DPPC/DLPC/cholesterol was visualized [22]. It was specu-
lated that there are many segregated microdomains coexist-
ing on the membrane of liposomes constituted by two dif-
ferent kinds of lipids. We hypothesized these microdomains
might prevent the aggregation of hydrophobic drug to form
crystal precipitates.
The aim of the study was to develop a novel liposomal
formulation, composed of naturally unsaturated and hydro-
genated PC with signiﬁcant phase transition temperature
diﬀerence, capable of incorporating high paclitaxel content.
The inﬂuences of the feeding ratio of hydrogenated PC to
total PC and the drug-to-lipid ratio on the particles size,
drug incorporation eﬃciency, phase transition temperature,
and the storage stability were evaluated. Additionally, in vitro
cytotoxicity of prepared paclitaxel-loaded liposomes on C-
26 colon cancer cell line was estimated. Moreover, plasma
exposure and acute toxicity of the paclitaxel liposomes
were studied in vivo. Finally, the antitumor eﬃcacy of the
paclitaxelliposomes inPC14PE6/AS2 bearing nudemicewas
also examined.
2.MaterialsandMethods
2.1. Materials. Egg phosphatidylcholine (EPC, Lipoid E100),
and hydrogenated egg phosphatidylcholine (HEPC, Lipoid
E PC-3) were obtained from Lipoid GmbH. Hydrogenated
soy phosphatidylcholine (HSPC, Epikuron 200 SH) were
obtained from Lucas Meyer GmbH. Paclitaxel was purchased
from Hauser Chemical Res, Inc. Methoxy polyethylene
glycol 2000-disteary phosphatidyl ethanolamine (MPEG)
was purchased from Shearwater Polymers, Inc. The other
chemicals were purchased from Sigma or Merck.
2.2. Preparation of Liposomes. Paclitaxel was added to the
alcoholic admixture of EPC, HEPC, cholesterol (Chol), and
MPEG with a given drug-to-lipid molar ratio as indicated
in the context. The solution was evaporated under vacuum
to remove the solvent and formed a lipid ﬁlm on the
wall of the round-bottom ﬂask at which time; aliquots of
10% (w/v) sucrose were added to the ﬂask for hydration.
Large multilamellar liposomes were suspended, and then
sonicated (XL2020, Misonix Inc., Farmingdale, NY, USA) for
10 minutes to yield small unilamellar liposomes. Paclitaxel-
containing liposomes underwent ﬁltration through a 0.2μm
cellulose acetate membrane (Orange Scientiﬁc Co., Braine L’
Alleud, Belgium) to remove possible paclitaxel precipitates
and achieve sterilization. Drug incorporation eﬃciency, rep-
resenting the retention of paclitaxel in the ﬁltered liposomes
with respect to the originally added drug, was determined by
HPLC analysis. Laser particle size analyzer (N4 Plus, Coulter
Electronics Inc., Hialeah, FL, USA) was used to measure the
average particle size. The liposomes were sealed in the vial
under nitrogen and stored at 4◦C for further shelf stability
test.
2.3. HPLC Assay. High performance liquid chromatography
(HPLC) was performed using an autosampler, controller,
and dual wavelength absorbance detector with wavelength
set to 229nm, all of which were obtained from Waters Co. A
125mm × 4mm Lichrosphere 100 RP-18 column, obtained
from Merck, was employed to identify and quantify the
concentration of paclitaxel. The mobile phase was composed
of 50% acetonitrile and 50% D.I. water eluted isocratically
throughout the measurement. A sample was dissolved in
methanol before injection into a 20μLs a m p l el o o p .T h e
retention time of paclitaxel is 12 minute while the ﬂow rate
was kept at 0.5mL/min.
2.4. Diﬀerential Scanning Calorimetry (DSC) Studies. DSC
measurements were performed using a diﬀerential scanning
calorimeter (Mettler-Toledo DSC 822e, Switzerland). The
liposome suspensions (total lipid concentration: 20mg/mL)
were heated at a programmed constant heating rate of 5◦C
per minute. Empty hermetically sealed aluminum pans were
used as reference.
2.5. Shelf Stability Analysis. Shelf stability of the paclitaxel
liposomes at 4◦C was monitored at the predetermined
interval time. Particle size was analyzed before ﬁltration of
thesampletoremovetheaggregatedliposomesandpaclitaxel
precipitates. The sample ﬁltered through 0.2μm cellulose
acetate membrane then was prepared for measurement of
paclitaxel concentration by HPLC.
2.6. Cytotoxicity Assay. C-26, a syngeneic colon tumor cell
line, was inoculated at 5 × 103 cells per well in 96-well
microtiter plate. The cells were maintained with RPMI-
1640 medium comprising 10% heat-inactivated fetal calf
serum, 100U/mL penicillin, and 100mg/mL streptomycin
at 37
◦Ci na5 %C O 2 humidiﬁed incubator. The drug-
containing solutions were added and incubated with cells for
72 hours before the MTT assay [23]. Liposome vehicle at the
comparable lipid concentration was used as the control. The
optical density readings were determined by an ELISA reader
at540nm.Cellsurvivalratewascalculatedbyinternalization
of the optical density readings.
2.7. Pharmacokinetic Studies. All animal studies, including
pharmacokinetic study, acute toxicity, and eﬃcacies of
prepared liposomes, were performed in compliance with
the “Guide for the Care and Use of Laboratory Animals”
prepared by the Institute of Laboratory Animal Resources,
National Research Council, USA and published by the
National Academy Press, revised in 1996.
For the pharmacokinetic studies, six to seven weeks old
female SD rats were purchased from the National Labora-
tories of Animal Breeding and Research Center (NLABRC,
Nangarng, Taipei, Taiwan). Rats were bred at least one
week after received to obtain a stable habitable condition
before any experiment. The jugular vein was cannulated
and the cannula was exteriorized in the back of the neck.
Taxol or liposomal paclitaxel was administrated through
the jugular vein at the paclitaxel dose of 5mg/kg rats.Journal of Drug Delivery 3
Table 1: Characteristics and shelf stability of liposomes mainly composed of either natural EPC or HEPC alone.
Liposome
composition [Lipid] (mM) Drug/PL
(mole%)
[Paclitaxel]
(mg/mL)
a
Mean particle
size (nm) I.E.b (%)
Remaining contentc (%)
14 days 30 days
EPC/Chol/MPEG 20 3 0.45 142.9 88.4 89.3 77.9
(20/8/1) 20 7 0.52 174.1 42.1 67.8 35.4
HEPC/Chol/MPEG
(20/8/1) 20 3 0.32 93.2 68.1 76.7 63.6
aConcentration of paclitaxel at day 0.
bIncorporation eﬃciency = paclitaxel incorporated in liposomes/paclitaxel added.
cRemaining content = [paclitaxel] at day N/[paclitaxel] at day 0.
Serial blood samples were withdrawn through the venous
catheter after the rats were awakened from anesthesia.
Drug concentrations in plasma were analyzed by HPLC.
The pharmacokinetic parameters of each formulation were
calculated using the WinNonLin pharmacokinetic software
(Version 3.1, Pharsight Co., Mountainview, CA, USA).
2.8. Acute Toxicity Test. Six to eight weeks old male ICR mice
were divided into four diﬀerent groups (treated with Taxol
20mg/kg, Taxol 40mg/kg, liposomal paclitaxel 20mg/kg,
or liposomal paclitaxel 40mg/kg), consisting of 5 mice in
each group. Mice for each group were injected through
tail vein to examine the acute intravenous toxicity. After
liposomeadministration,themicewereobservedfor14days.
During the observation period, mice were observed daily for
mortality and clinical signs. The survival rate over 14 days
was obtained.
2.9. Eﬃcacy Test. Athymic BALB/c nude mice were obtained
from NLABRC and weighted 20–22g at the start of the
experiments.Themicewerehousedinsterilizedﬁlter-topped
cages and maintained in sterile conditions. The human
lung adenocarcinoma cell line PC14PE6/AS2, a derivative
of PC14PE6, which was obtained from Dr. Wu-Chou Su
(National Chung Kung University medical college, Taiwan).
The PC14PE6/AS2 cells express higher VEGF proteins,
microvessel density, and vascular permeability in tumors
[24]. It was suggested that the enhanced permeability and
retention (EPR) eﬀect within the tumor site made colloidal
systems more eﬀective on the treatment of cancer [25].
On the day of implantation, 106 cells were inoculated
subcutaneously into lower back for each mouse. Tumor
volume was determined by measuring orthogonal diameters
ofthetumorandcalculatedas0.4 ×(a2×b),where“a”isthe
tumor width and “b” is its length in mm. Tumor formation
measuring at least 250mm3 was considered a positive take
(day 0), at which time 4 groups, each contained 6 animals,
were established. They were (1) normal saline control group,
(2) Taxol 20mg/kg treatment group, (3) liposomal paclitaxel
20mg/kg treatment group, and (4) liposomal paclitaxel
40mg/kg treatment group. The drugs and controls were
given as a bolus into tail veins for 4 doses totally on day 1,
3, 6, and 9. Animal mortality was checked daily, and tumor
volume and body weight was checked every other day. Mice
showing more than 20% body weight loss or tumors larger
than 10-fold of original size (∼2,500mm3)w e r es a c r i ﬁ c e d .
3. Results
3.1. Liposomes Made of Single PC. The liposomes composed
of either HEPC or EPC alone were prepared according to
theproceduredescribedinExperimentalSection.MPEGwas
used in the formulation to stabilize liposomes. The MPEG
to phospholipid molar ratio was limited to less than 5% to
avoid misinterpretation with the combinative formulation
[26]. The cholesterol compositions were optimized to obtain
the small liposome size and high drug incorporation. The
results in Table 1 showed that the liposomes made mainly
of EPC incorporated up to 88% paclitaxel when the drug
to phospholipid molar ratio was kept at 3%. However,
drug incorporation eﬃciency fell to 42% when the drug to
phospholipid molar ratio rose to 7%. The liposomes made
of HEPC incorporated below 70% paclitaxel when drug to
phospholipid molar ratio was kept at 3%. The liposomes
would yield apparent white precipitates while paclitaxel to
phospholipid molar ratio was elevated above 3%. The higher
drug incorporation eﬃciency for EPC liposomes resulted
from the lower transition temperature of EPC (<0◦C) that
is ﬂexible enough to entrap relatively more hydrophobic
molecules rather than rigid HPEC [27]. Table 1 also presents
the shelf stability of the liposomes composed principally of
eitherHEPCorEPC.Theseliposomesweremonitoredat4◦C
only for one month because of the early appearance of white
precipitates. A decrease in drug incorporation eﬃciency in
the liposomes was conﬁrmed by HPLC. The EPC liposomes
exhibited an obvious decline in drug incorporation as the
drug to phospholipid molar ratio was increased to 7%. The
HEPC liposomes were considerably unstable too.
3.2. Combinative Formulation of Hydrogenated PC and Nat-
ural PC. Two distinct phosphatidylcholines with signiﬁcant
phase transition temperature diﬀerence were used in this
study. HEPC is referred to as a phospholipid with high
phase transition temperature, anticipated to be about 50–
60
◦C. Natural EPC containing high content of unsaturated
fatty acid chains is considered to have low-phase transition
temperature below 0◦C. A series of combinations of HEPC
and EPC were investigated in an attempt to develop a
stable liposome formulation for paclitaxel. Besides, 5mol%
MPEG and 10mol% cholesterol to phospholipid molar
ratio were added to costabilize the liposomes. Their eﬀects
of MPEG and cholesterol on paclitaxel incorporation and
particle size were minimized by the constant molar ratio.4 Journal of Drug Delivery
Table 2: Paclitaxel incorporation eﬃciency and particle size
of the liposomes made of EPC and HEPC. Liposomes were
prepared in accordance to the formulation (paclitaxel/total
PC/cholesterol/MPEG = 0.3/10/1/0.5).
Molar ratio of HEPC/total
PC (%)
Mean particle size
(nm) I.E. (%)
25 113.3 69.2
43 120.8 63.8
62 128.4 73.6
81 202.6 37.6
Table 3: Eﬀects of increasing paclitaxel to lipid molar ratio
on physical properties of liposomes. Liposome formulation is
composedofPCs,cholesterol,andMPEGattheoptimalmolarratio
(EPC/HEPC/Chol/MPEG = 15/5/2/1).
PC
(mM)
Drug/PL
a
(mole%)
[Paclitaxel]
(mg/mL)
Mean particle
size (nm) I.E. (%)
20 7 1.0 114.3 84.5
40 7 2.0 115.8 82.4
20 10 1.3 116.2 78.8
20 15 2.1 125.4 81.0
20 20 2.9 134.9 85.1
20 25 2.3 146.3 54.6
aPL represents total phospholipids including EPC, HEPC and MPEG.
The characteristics of the formulated liposomes are given in
Table 2. When increasing HEPC molar ratio, this led to an
increase in the average diameter of the liposomes. Mean-
while, the incorporation eﬃciency of paclitaxel gradually
decreased as the quantity of HEPC increased. The particle
size could be reduced but drug incorporation eﬃciency did
not change signiﬁcantly when HEPC molar ratio decreased
below 62%. Therefore, 25% molar ratio of HEPC, with the
smallest particle size among the tested compositions, was
selected to test the drug loading capacity of the liposome
formulation.
3.3. Increasing Drug/Phospholipid Ratio. Drug loading
capacity of the formulated liposomes described above was
investigated by further increasing paclitaxel to phospholipid
molar ratio from 7% to 25%. Phospholipids represent
HEPC, EPC, and MPEG. Drug to phospholipid molar ratio
represents the originally added drug content. The eﬀects of
increasing drug to phospholipid ratio were examined on
the physical properties of drug incorporation and particle
size. Table 3 lists the drug incorporation eﬃciency and
particle size of the resultant liposomes. It was noteworthy
that high paclitaxel content was eﬀectively incorporated in
the liposomes. The incorporation eﬃciency was maintained
above 80% even though the drug to phospholipid molar
ratio was increased to 20%. No precipitate was observed
throughout preparation.
The drug loading capacity of the liposomes was found
to be paclitaxel concentration dependent. Attempts to
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Figure 1: The DSC thermographs for the EPC/HEPC (4:1)
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paclitaxel.
incorporate extremely high paclitaxel tended to destabilize
liposomes. The drug incorporation eﬃciency dropped to
55% when the drug to phospholipid molar ratio was
increased to 25%. Such a high paclitaxel loading acceler-
ated destabilization of liposomes. White precipitates and
aggregated liposomes appeared shortly after sonication.
Needle-like precipitates and many ﬂoccules can be seen by
optical microscope. The poor drug incorporation and lipid
aggregation reﬂects instability of the liposomes with such a
high drug to phospholipid ratio. Therefore, the maximum
drug loading in the stable liposomes during preparation
was anticipated to 20mole%. Besides, liposome solutions
with various lipid concentrations were also prepared and
examined. It is evident that doubling lipid content (40mM)
with the same liposome composition aﬀected neither drug
incorporation nor particle size.
3.4. Phase Transition Temperature of Prepared Liposomes.
To determine the inﬂuence of paclitaxel on phospholipid
bilayer phase transitions, the DSC analysis was employed.
The DSC thermographs for the EPC/HEPC (4:1) liposomes
without the drug as well as with 7 and 14mol% paclitaxel
are shown in Figure 1. For the EPC/HEPC liposome, a low
miscibility was observed that leads to a phase separation in
the temperature range of 39–44◦C. It can be observed from
Figure 1 that with increasing the paclitaxel concentration
in liposomes, the main transition temperature was shifted
slightly to a lower temperature from 41
◦Ct o3 9 .5
◦C.
3.5. Shelf Stability. Liposomal paclitaxel were stored at 4◦C
immediately after preparation and sterilization. Particle size
(Figure 2(a))andpaclitaxelconcentration(Figure 2(b))wer e
measured periodically. The results in Figure 2 indicate that
these two measurements were stable for most of the formu-
lations over six months. The implication of shelf stability
of the liposomes with paclitaxel to lipid ratio was revealed.
At 25% of drug to phospholipid molar ratio the liposomesJournal of Drug Delivery 5
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Figure 2:Shelfstabilityoftheliposomeswithincreasingdrug/phospholipidmolarratioat4◦C.Legendsmeanthepaclitaxeltophospholipid
molar ratio of the liposomes. The composition is tabulated in Table 2.
was rather unstable in both terms of drug incorporation
and particle size. Particle size rose and drug incorporation
fell apparently. Although the 20% liposomes possessed more
than 80% of incorporation eﬃciency at the beginning of
storage, drug incorporation declined much more and faster
than those of the other with a lower drug-to-lipid ratio.
After six-month storage, the retention of paclitaxel in the
liposomes dropped to 67% of the originally incorporated
amount. The particle size increased from 146 to 168nm
within the ﬁrst two months. When the drug to phospholipid
molar ratio was maintained equal or below to 15%, all the
formulated liposomes remained stable for at least 6 months.
The particle size varied by 10nm in maximum and almost
unchanged drug incorporation occurred. A maximum drug
loading capacity of the liposomes, which could be stable
in long-term storage, thus was anticipated to be 15%–20%
drug-to-lipid molar ratio.
3.6. Cytotoxicity. The liposome formula with 15% pacli-
taxel was preceded with the cytotoxicity, acute toxicity,
and pharmacokinetic tests. The paclitaxel concentration of
the liposomes for 50% inhibition of C-26 cells (IC50)i s
approximately 162nM which is slightly higher than that of
Taxol (IC50 = 105nM), as shown in Figure 3. The liposome
vehicles without paclitaxel showed no cytotoxicity against C-
26 tumor cells over the tested range.
3.7. Pharmacokinetic Studies. Figure 4 and Table 4 show
the plasma concentration proﬁle of paclitaxel and their
pharmacokinetic parameters, respectively, after i.v. injection
of liposomes and Taxol in rats. The AUC value of paclitaxel
liposomes was slightly higher than that of Taxol. However,
the liposomal paclitaxel in plasma declined quicker than
Taxol. It seems that incorporation of MPEG in the prepared
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Figure 3: Survival rates of C-26 tumor cells exposing to the
liposomes with or without paclitaxel and Taxol. The amount of the
liposomes corresponding to the paclitaxel liposome was added as
the control.
liposome formulations did not prolong their circulation
time.
3.8. Acute Toxicity. Escalated dose of paclitaxel liposomes
was tested in ICR mice to determine the acute toxicity. Mice
were divided into two groups treated with Taxol or liposomal
paclitaxel at doses of 20 and 40mg/kg, respectively. Table 5
shows the survival rate in all the groups over 14 days. It was6 Journal of Drug Delivery
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Figure 4: Plasma concentration proﬁles of paclitaxel after i.v.
injection of Taxol or paclitaxel liposomes in rats (5mg/kg as
paclitaxel). Each data represents the mean of 4 rats.
Table 4: Mean pharmacokinetic parameters of paclitaxel after i.v.
injections of Taxol or paclitaxel liposomes at a dose of 5mg/kg in
rats.
T1/2 (hour) AUC0→∞(μgh/mL)
Taxol 2.4 ±0.48 .5 ±1.7
Liposomal paclitaxel 2.1 ±1.01 2 .7 ±5.8
Table 5: Survival rate of mice received i.v. injections of Taxol or
paclitaxel liposomes at doses of 20 and 40mg/kg.
Dose (mg/kg) Survival Rate
Taxol 20 4/5
40 1/5
Liposomal paclitaxel 40 8/8
found that 3 of 5 mice with 40mg/kg of Taxol group died on
the same day of injection. Afterwards, one of the other mice
died on the third day. In contrast, all the mice in liposomal
paclitaxel group survived over the test period of 14 days.
3.9.EﬃcacyTest. Theantitumoreﬃcacyofdistinctpaclitaxel
formulations was studied in AS-2 lung cancer bearing nude
mice. In the case of the paclitaxel liposomes, weight loss was
observed at a dose of 40mg/kg. One mouse died on day 7
and one on day 11. It was estimated the toxicity due to the
repeated doses of the paclitaxel liposomes. In the case of
Taxol at a dose of 20mg/kg, an evidence that one mouse died
on day 6 also indicated the repeated dose toxicity. Because
Taxol at a dose of 40mg/kg had caused a high mortality in
nude mice (>50%) in a preliminary study, we excluded the
doselevelinthecurrentstudy.Figure 5(a)showstheprogress
of the tumor growth observed for 28 days. It was found
that the tumor size of the normal saline group increased
signiﬁcantly with time. In contrast, the groups injected
with distinct paclitaxel formulations signiﬁcantly delayed
the tumor growth as compared to the normal saline group
(P<. 05). At the same dose of 20mg/kg, liposomal paclitaxel
seemed to delay the tumor growth more eﬀectively than
Taxol. Once increasing the dose to 40mg/kg, the liposomal
paclitaxel signiﬁcantly inhibit the tumor growth for more
than 42 days as compared with other treated groups (P<
.05). Although two mice died during dosing treatment for
thehighdoseofliposomalpaclitaxel,theliposomalpaclitaxel
(20 and 40mg/kg) signiﬁcantly enhanced the mouse survival
time to more than 30 days as compared with saline group
(Figure 5(b), P<. 05). The median survival time for mice
treated with normal saline was 12.3 days, and treatment with
Taxol slightly increased this survival to 19.7 days. Thus, the
prepared liposomal paclitaxel provide beneﬁts on reducing
tumor volume, which correlated with a substantial increase
in animal survival.
4. Discussion
Balasubramanian et al. reported that paclitaxel has a
tendency to undergo concentration-dependent aggregation
in hydrophobic or relatively low polarity environments,
forming intermolecular hydrogen bonds [28]. Restated, as a
large amount of paclitaxel is embedded in the hydrophobic
domain within the bilayer membrane, it is thermodynam-
ically prone to self-aggregating, and thereby destabilizing
the liposomes [29]. The results imply the limited drug
loading and the poor shelf stability of the current lipo-
some formulations for paclitaxel. Much research [12–15,
19] also supported the fact that the optimal paclitaxel to
lipid molar ratio in the previous liposome formulations
is from 3% to 4%, and the liposomes is shelf stable only
when the drug-to-lipid molar ratio is kept equal to or
below 3%. A higher drug-to-lipid molar ratio would lead
to the occurrence of needle-like crystal precipitate during
preparation.
To improve instability and poor drug payload of the
conventional paclitaxel liposomes, we developed a formu-
lation combining two sorts of PCs into liposomes, which
have signiﬁcant diﬀerences between their phase transition
temperatures. Based on the material information provided
by the manufacture, HEPC is referred to a phospholipid with
long hydrocarbon chain length and high phase transition
temperature of 50–55
◦C; on the contrary, the other (natu-
rally occurring EPC) containing high content of unsaturated
fatty acid chains is considered to have a lower phase
transition temperature of −8◦C. The diﬀerence of phase
transition temperatures between the two PCs is estimated
to 60
◦C at least. It could be speculated that the separated
phases,agelphaseandﬂuid(liquid-crystal)phase,onbilayer
membrane at a given temperature were formed, like the
giant unilamellar liposomes made of DPPC and DLPC and
visualized by confocalmicroscope [22,30]. Moreover,gel-gel
[31, 32] and ﬂuid-ﬂuid [33] demixing of the binary phos-
pholipid system have also been observed, especially when
their hydrocarbon chain lengths are mismatched. Therefore,Journal of Drug Delivery 7
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Figure 5: (a) The ratio of tumor size changed and (b) survival rate of diﬀerent paclitaxel formulations on human lung adenocarcinoma
(AS-2) bearing nude mice.
a combination of two phospholipids including HEPC and
natural EPC is reasonably expected to produce liposomes
with the many segregated microdomains coexisting on the
membrane.
Accordingly, formation of the phase boundary was
speculated to restrict the lateral diﬀusion across segregated
domains, hindering the self-aggregation of hydrophobic
molecules.Astableliposomeformulationabletoincorporate
a high content of paclitaxel, therefore, can be made. The
coexistence of lateral separate phospholipid regions pro-
motes the incorporation of a large amount of hydrophobic
paclitaxel into the phospholipid bilayer. The hypothesis may
account for why the liposomes formulated in this study can
incorporate more paclitaxel and remain more stable in long-
term storage. The drug to phospholipid molar ratio can
be increased to 15%, which was signiﬁcantly upgraded by
approximately sixfolds in comparison to the other liposome
formulations reported [12–15, 19]. The liposomes consisting
of a combination of two phospholipids showed improved
drug loading capacity and shelf stability over those of the
formulations with single phospholipid alone. The features
evenaresuperiortothepreviousliposomeformulationswith
negatively charged phospholipids [11–14, 21]. Furthermore,
the liposomes still alleviate acute toxicity without changing
its cytotoxicity against tumor cells, resembling the other
liposome formulations [2, 14, 21, 34, 35]. Pharmacokinetic
data also exhibits a higher AUC in rats than Taxol. Despite,
the liposomes were not able to circulate in blood as long
as those composed of MPEG on the surface. This result
may be attributed to the presence of reticuloendothelial
(RES) system. Nanoparticles will usually be taken up by the
liver, spleen, and other parts of the RES depending on their
surface characteristics, especially for particles with more
hydrophobic surfaces [36, 37]. However, the RES uptake of
liposomal paclitaxel may limit the systemic exposure of non-
RES tissues, such as the bone marrow, to paclitaxel [37]. Due
to the alternant biodistribution of paclitaxel by liposomes,
it may exert not only a direct eﬀect on reduced toxicity
but also may underlie the preservation or enhancement of
antitumor eﬃcacy following administration of liposomal
paclitaxel [37]. Regardless of the similar proﬁle of the blood
exposure to Taxol, the prepared liposomal paclitaxel did
demonstrate the reduced toxicity and increase the eﬃcacy
against human cancer in animal model.
5. Conclusion
This study presents a novel liposomal formulation capable of
incorporating ahighpaclitaxel content,andremainingstable
in long-term storage as well. Liposomes remained stable in
liquid form at 4◦C for at least 6 months when the drug-
to-lipid molar ratio was below 15%. In aspects of in vitro
and in vivo eﬃcacy studies, the paclitaxel liposomes exhibit a
comparable cytotoxicity against colon cancer and enhanced
eﬃcacy against human lung tumor as compared with
Taxol. As expected, the liposomes have lower acute toxicity
signiﬁcantly in mice than the current cremophore/alcohol
formulation dose. These results demonstrate that the liposo-
mal paclitaxel is promising as an anticancer treatment. The
novel formulation has a potential to incorporate the high
content of hydrophobic drug stably.
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